Nukkleus Inc. (NUKK) is having one of those days where good news doesn't quite translate into good vibes. Shares of the defense holdings company dropped Wednesday afternoon, even as the company rolled out some seemingly positive developments on both the capital-raising and operational fronts.
The SPAC and the Iron Dome
Nukkleus announced it's taking SC II Acquisition Corp public, a newly formed SPAC where Nukkleus owns the majority of the sponsor entity. The IPO is priced at $10 per unit and expects to raise $150 million in gross proceeds, with the deal set to close around Friday. That's a solid chunk of capital, though the market's reaction suggests investors might be taking a wait-and-see approach.
Meanwhile, on Tuesday, the company shared news that Rimon, a business Nukkleus is in the process of acquiring, will play a key role in Israel's massive Iron Dome expansion. Rimon supplies critical power and subsystem components for the Iron Dome missile defense system, and Israel's Ministry of Defense just approved a multi-billion-dollar expansion of the program.
The expansion is largely funded through an $8.7 billion U.S. defense assistance package, with $5.2 billion earmarked specifically for Israel's air-defense systems. It's one of the largest production investments in Iron Dome history, which positions Rimon as a significant beneficiary of the spending surge.
Technical Picture: Not Pretty
Despite the headlines, Nukkleus is struggling from a technical standpoint. The stock is trading roughly 14.8% below its 50-day moving average of $7.09 and about 41.7% below its 200-day moving average of $10.37. Those numbers paint a bearish picture, suggesting momentum has been elusive.
The relative strength index sits at 52.69, which is neutral territory, but that could shift quickly if selling pressure continues. Support appears at $5.18, a level that could serve as a critical floor in the near term. If that breaks, the stock could slide toward its 52-week low. On the upside, resistance is at $6.66, a threshold traders will be watching for any signs of reversal or breakout.
Right now, Nukkleus is at a crossroads. A sustained drop below support would signal more weakness ahead, while pushing past resistance could hint at a potential recovery. Given the volatility, these key levels deserve close attention.
Price Action: Nukkleus shares were down 4.69%, trading at $5.97 at the time of publication.
